33,813 Shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) Bought by Brevan Howard Capital Management LP

Brevan Howard Capital Management LP bought a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 33,813 shares of the company’s stock, valued at approximately $637,000. Brevan Howard Capital Management LP owned 0.07% of Pacira BioSciences at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its stake in shares of Pacira BioSciences by 0.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,992,601 shares of the company’s stock valued at $37,541,000 after acquiring an additional 13,604 shares during the last quarter. Geode Capital Management LLC raised its holdings in Pacira BioSciences by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,091,970 shares of the company’s stock worth $20,578,000 after purchasing an additional 5,071 shares during the period. Northern Trust Corp raised its holdings in Pacira BioSciences by 30.8% in the fourth quarter. Northern Trust Corp now owns 616,891 shares of the company’s stock worth $11,622,000 after purchasing an additional 145,205 shares during the period. Impax Asset Management Group plc grew its holdings in shares of Pacira BioSciences by 14.8% in the 4th quarter. Impax Asset Management Group plc now owns 540,027 shares of the company’s stock valued at $10,174,000 after buying an additional 69,424 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Pacira BioSciences by 16.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company’s stock valued at $9,462,000 after buying an additional 70,307 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Stock Down 1.1 %

PCRX stock opened at $24.90 on Friday. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -12.27 and a beta of 0.56. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $31.67. The business has a 50 day moving average price of $24.70 and a two-hundred day moving average price of $22.05. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51.

Analysts Set New Price Targets

Several research firms have weighed in on PCRX. HC Wainwright lifted their target price on Pacira BioSciences from $48.00 to $65.00 and gave the stock a “buy” rating in a report on Tuesday, April 8th. Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and raised their target price for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. Royal Bank of Canada reissued a “sector perform” rating and set a $18.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, April 8th. Finally, Barclays increased their target price on Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $26.67.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.